CAVA Group Inc vs ResMed Inc. — how do they compare? CAVA Group Inc trades at $67.81 (market cap $7.17B), while ResMed Inc. trades at $223.62 (market cap $31.92B). The key difference: ResMed Inc. is far larger — about 4.5× CAVA Group Inc's market cap, and ResMed Inc. pays a 1.2% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| CAVA | RMD | |
|---|---|---|
Market Cap | $7.17B | $31.92B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $293.73 |
52-Week Low | $43.59 | $182.82 |
Enterprise Value | $7.32B | $31.28B |
Dividend Yield | — | 1.2% |
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.
Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →